ScholarIQanswers from OpenAlex & ORCID
Satoshi Morita
ResearcherPublications, citations & collaboration network
Satoshi Morita is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Satoshi Morita have?
ScholarIQindexed works
Satoshi Morita has 1,267 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Satoshi Morita have?
ScholarIQcitation count
Satoshi Morita has 41,011 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Satoshi Morita?
ScholarIQh-index
Satoshi Morita has an h-index of 85 in OpenAlex.
What is the i10-index of Satoshi Morita?
ScholarIQi10-index
Satoshi Morita has an i10-index of 523 in OpenAlex.
What is the ORCID of Satoshi Morita?
ScholarIQorcid
The ORCID for Satoshi Morita is on the source record.
What is the OpenAlex record for Satoshi Morita?
ScholarIQopenalex
The OpenAlex for Satoshi Morita is on the source record.
What are the most-cited papers on Satoshi Morita?
ScholarIQmost cited works
Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma
Manabu Morimoto, Kazushi Numata, Masaaki Kondou, Akito Nozaki, Satoshi Morita, Katsuaki Tanaka
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa, Hideo Tanaka, Masaya Okada, Hirohisa Nakamae, Masayuki Hino, Kazunori Murai, Yoji Ishida, Takashi Kumagai, Seiichi Sato, Kazuteru Ohashi, Hisashi Sakamaki, Hisashi Wakita, Nobuhiko Uoshima, Yasunori Nakagawa, Yosuke Minami, Masahiro Ogasawara, Tomoharu Takeoka, Hiroshi Akasaka, Takahiko Utsumi, Naokuni Uike, Tsutomu Sato, Sachiko Ando, Kensuke Usuki, Satoshi Morita, Junichi Sakamoto, Shinya Kimura
2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease
Hiroyasu Yamamoto, Shinichi Nishi, Tadashi Tomo, Ikuto Masakane, Kazuhide Saito, Masaomi Nangaku, Motoshi Hattori, Takahiro Suzuki, Satoshi Morita, Akira Ashida, Yasuhiko Ito, Takahiro Kuragano, Yasuhiro Komatsu, Ken Sakai, Yoshiharu Tsubakihara, Kazuhiko Tsuruya, Terumasa Hayashi, Hideki Hirakata, Hirokazu Honda
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto, Akihiro Tsuboi, Yoshitaka Oka, Tsuyoshi Suzuki, Tetsuo Hashiba, Naoki Kagawa, Naoya Hashimoto, Motohiko Maruno, Olga A. Elisseeva, Toshiaki Shirakata, Manabu Kawakami, Yusuke Oji, Sumiyuki Nishida, Satoshi Ohno, Ichiro Kawase, Jun Hatazawa, Shin‐ichi Nakatsuka, Katsuyuki Aozasa, Satoshi Morita, Junichi Sakamoto, Haruo Sugiyama, Toshiki Yoshimine
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto